Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma

Leukemia volume 16, pages 1838–1843 (2002)Cite this article

Abstract

This report describes the long-term outcome of a cohort of 127 de novo multiple myeloma patients treated with at least one course of high-dose therapy (HDT) in a single institution between June 1985 and December 1995, for whom the minimum follow-up duration for survivors is 6 years. The 12-year overall survival (OS) and event-free survival (EFS) rates are 24.9% and 3.1%, respectively, and the median survival and EFS are 49 and 17 months, respectively. Only four patients are alive and disease-free 79, 90, 132 and 153 after the first HDT, respectively. Three of them received a subsequent allogeneic bone marrow transplantation. Three factors significantly influence OS in this series: B2M at diagnosis, age, and the completion of a second HDT. The 10-year survival is 18.9% for the group of patients with B2M level >3 mg/l at diagnosis as compared with 41% for patients with B2M ⩽3, with a median survival of 31 months vs 73 (P = 0.01). The 10-year survival is 23.4% for the group of patients aged >55 years as compared with 36.5% for patients aged <55 years, with a median survival of 34.5 months vs 70.5 (P = 0.04). The 10-year survival is 20.4% for the group of patients who did not receive a second HDT as compared with 35.2% for patients who completed a second HDT, with a median survival of 29 months vs 70 (P = 0.02). In this study we show that some patients treated with HDT experience durable remission and prolonged survival. This survival is significantly influenced by age (⩽55 years), B2M at diagnosis (⩽3 mg/l) and by the completion of two cycles of HDT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. McElwain TJ, Powles RL . High dose intravenous melphalan for plasma-cell leukaemia and myeloma Lancet 1983 ii: 822–824

    Article  Google Scholar 

  2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 1996 335: 91–97

    Article  CAS  Google Scholar 

  3. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G . Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793

    CAS  PubMed  Google Scholar 

  4. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Lanng Nielsen J, Wislöff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen H, Lamvik J, Löfvenberg E, Nesthus I, Rödjer S . Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study Blood 2000 95: 7–11

    CAS  Google Scholar 

  5. Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby PJ, Norman A, Raymond J, Powles R . High-dose melphalan for multiple myeloma: long-term follow-up data J Clin Oncol 1994 12: 764–768

    Article  CAS  Google Scholar 

  6. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, Tricot G, Alexanian R . Long-term follow-up after high-dose therapy for high-risk multiple myeloma Bone Marrow Transplant 1998 21: 1101–1107

    Article  CAS  Google Scholar 

  7. Reece DE, Brockington DA, Phillips GL, Barnett MJ, Klingemann HG, Nantel SH, Sutherland HJ, Shepherd JD . Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma Bone Marrow Transplant 2000 26: 621–626

    Article  CAS  Google Scholar 

  8. Powles R, Sirohi B, Treleaven J, Singhal S, Kulkarni S, Lal R, Riggs A, Horton C, Saso R, Mehta J . Continued first complete remission in multiple myeloma for over 10 years: a series of operationally cured patients Blood 2000 96 (Suppl. 1): 515a

    Google Scholar 

  9. Bjorkstrand BT, Svensson H, Goldschmidt H, Ljungman PT, Apperley J, Remes K, Marcus R, Barbui T, Alegre A, Majolino I, Carlson K, Boogaerts M, Coser P, Iriondo A, Sureda A, Lenhoff S, de Laurenzi A, Bladé J, Ferrant A . Autotransplants in multiple myeloma – a registry study from the European Group for Blood and Marrow Transplantation Blood 1999 94 (Suppl. 1): 714a

    Google Scholar 

  10. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents N Engl J Med 1984 310: 1353–1356

    Article  CAS  Google Scholar 

  11. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F, Frieri R, Gallamini A, Gallone G, Giovangrossi P, Grignani F, Lauta VM, Liberati M, Musto P, Neretto G, Petrucci MT, Resegotti L, Pileri A, Mandelli F . Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is nt superior to melphalan and prednisone even in high-risk patients J Clin Oncol 1991 9: 444–448

    Article  CAS  Google Scholar 

  12. Moreau P, Fière D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL . Prospective randomized placebo-controlled study of granulocyte–macrophage colony-stimulating factor without stem-cell trnsplantation after high-dose melphalan in patients with multiple myeloma J Clin Oncol 1997 15: 660–666

    Article  CAS  Google Scholar 

  13. Moreau P, Milpied N, Mahé B, Juge-Morineau N, Rapp MJ, Bataille R, Harousseau JL . Melphalan 220mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma Bone Marrow Transplant 1999 23: 1003–1006

    Article  CAS  Google Scholar 

  14. Kaplan EL, Meier P . Non parametric estimation from incomplete observations J Am Stat Assoc 1953 53: 457–481

    Article  Google Scholar 

  15. Peto R, Peto J . Asymptomatically efficient invariant procedures J R Stat Soc A 1972 135: 185–206

    Article  Google Scholar 

  16. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J . Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities Blood 2000 95: 4008–4010

    CAS  PubMed  Google Scholar 

  17. Lortholary O, Ascioglu S, Moreau P, Herbrecht R, Marinus A, Casassus P, De Pauw B, Denning DW . Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome Clin Infect Dis 2000 30: 41–46

    Article  CAS  Google Scholar 

  18. Attal M, Harousseau JL, Facon T, Michaux JL, Guilhot F, Fruchard C, Fuzibet JG, Hulin C, Caillot D, Dorvaux V, Cahn JY, Grosbois B, Stoppa AM, Ifrah N, Sotto JJ, Pignon B, Payen C . Single versus double transplantation in myeloma: a prospective and randomized trial of the Intergroupe Français du Myélome Blood 2000 96 (Suppl. 1): 557a

    Google Scholar 

  19. Bjorsktrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Bladé J, Carlson K, Cavo M, Ferrant A, Goldstone AH, deLaurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G . Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 1996 88: 4711–4718

    Google Scholar 

  20. Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Björkstrand B, Bladé J, Cornelissen J, deLaurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser, Powles R, Reiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L . Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres Br J Haematol 2001 113: 209–216

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University Hospital, Nantes, France

    P Moreau, R Misbahi, N Milpied, N Morineau, B Mahé, M Vigier, MJ Rapp, R Bataille & JL Harousseau

Authors
  1. P Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Misbahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Morineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Mahé
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Vigier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. MJ Rapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Bataille
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. JL Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moreau, P., Misbahi, R., Milpied, N. et al. Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma. Leukemia 16, 1838–1843 (2002). https://doi.org/10.1038/sj.leu.2402613

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402613

Keywords

This article is cited by

Search

Advanced search

Quick links